FOXP3 and depressive symptom measurement: In male patients, significantly higher methylation was determined at FOXP3 enhancer, sequence 2, CpG 4 (0.84 ± 0.70%) and 5 (1.16 ± 1.33%) in the case of depression compared to male patients without depression (position 4 (0.51 ± 0.37%) and 5 (0.51 ± 0.33%); p = 0.039 and p = 0.006, respectively).